Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Psychedelics Business

News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
Jeeshan Chowdhury, MD, PhD
Q&A
With Psychedelic Treatments on Horizon, New Opportunities Coming for Behavioral Healthcare Organizations
12/26/2023
Journey Colab founder and CEO Jeeshan Chowdhury, MD, PhD, discusses steps that providers should be taking to prepare for the impending approval of psychedelic-assisted therapies.
Journey Colab founder and CEO Jeeshan Chowdhury, MD, PhD, discusses steps that providers should be taking to prepare for the impending approval of psychedelic-assisted therapies.
Journey Colab founder and CEO...
12/26/2023
Behavioral Healthcare Executive
News
Delix Receives NIDA Grant to Advance Neuroplastogen for SUD
12/19/2023
Delix Therapeutics has been awarded a $320,000 grant from the National Institute on Drug Abuse to support the advancement of its novel neuroplastogen and non-hallucinogenic ibogaine analog, DLX-007.
Delix Therapeutics has been awarded a $320,000 grant from the National Institute on Drug Abuse to support the advancement of its novel neuroplastogen and non-hallucinogenic ibogaine analog, DLX-007.
Delix Therapeutics has been...
12/19/2023
Behavioral Healthcare Executive
News
AMA Releases Full Language of New CPT Code for Psychedelic Therapies
07/06/2023
The new Current Procedural Terminology III code for continuous in-person monitoring and intervention during psychedelic medication therapy will go into effect on January 1, 2024.
The new Current Procedural Terminology III code for continuous in-person monitoring and intervention during psychedelic medication therapy will go into effect on January 1, 2024.
The new Current Procedural...
07/06/2023
Behavioral Healthcare Executive
News
Psychedelics Business Briefs: MAPS PBC, Johns Hopkins Center, Numinus Wellness
06/22/2023
MAPS Public Benefit Corporation has reached an agreement to use NIDA data in its new drug application for MDMA-assisted therapy, the Johns Hopkins Center for Psychedelic & Consciousness Research has a new director, and Numinus Wellness is...
MAPS Public Benefit Corporation has reached an agreement to use NIDA data in its new drug application for MDMA-assisted therapy, the Johns Hopkins Center for Psychedelic & Consciousness Research has a new director, and Numinus Wellness is...
MAPS Public Benefit Corporation...
06/22/2023
Behavioral Healthcare Executive
News
Numinus Partners With MAPS on Psychedelic Experiential Training Initiative
06/15/2023
Numinus Wellness announced it is partnering with the Multidisciplinary Association for Psychedelic Studies to support experiential opportunities for practitioners as part of a clinical study. The company has also named a new CFO.
Numinus Wellness announced it is partnering with the Multidisciplinary Association for Psychedelic Studies to support experiential opportunities for practitioners as part of a clinical study. The company has also named a new CFO.
Numinus Wellness announced it is...
06/15/2023
Psych Congress Network
News
Psychedelic Business Briefs: COMPASS Pathways, MAPS PBC, Delix Therapeutics
05/10/2023
The American Medical Association has approved a CPT III code for psychedelic therapies submitted by COMPASS Pathways and MAPS Public Benefit Corporation, and Delix Therapeutics has initiated a phase I trial for a novel compound.
The American Medical Association has approved a CPT III code for psychedelic therapies submitted by COMPASS Pathways and MAPS Public Benefit Corporation, and Delix Therapeutics has initiated a phase I trial for a novel compound.
The American Medical Association...
05/10/2023
Behavioral Healthcare Executive
News
Numinus Ramps Up Expansion With Clinic Licensing Program
04/17/2023
Numinus Wellness has announced the launch of a clinic licensing model that will allow independent practitioners to own and operate mental health clinics under the Numinus Wellness brand.
Numinus Wellness has announced the launch of a clinic licensing model that will allow independent practitioners to own and operate mental health clinics under the Numinus Wellness brand.
Numinus Wellness has announced...
04/17/2023
Behavioral Healthcare Executive
News
Online Hormone Therapy Provider Signs LOI to Acquire Ketamine Wellness Centers
04/04/2023
Peter/PetraMD, an online provider of hormone therapy for men and women in the US, announced on Monday that it has signed a letter of intent to purchase Delic Holdings Corp.’s recently shuttered Ketamine Wellness Centers (KWC), the...
Peter/PetraMD, an online provider of hormone therapy for men and women in the US, announced on Monday that it has signed a letter of intent to purchase Delic Holdings Corp.’s recently shuttered Ketamine Wellness Centers (KWC), the...
Peter/PetraMD, an online...
04/04/2023
Behavioral Healthcare Executive
News
Numinus Wellness Launches Psychedelic-Assisted Therapy Training Certification Program
03/29/2023
Numinus Wellness has unveiled a psychedelic-assisted therapy training program that will develop practitioners’ core skills through multimodal teaching methods.
Numinus Wellness has unveiled a psychedelic-assisted therapy training program that will develop practitioners’ core skills through multimodal teaching methods.
Numinus Wellness has unveiled a...
03/29/2023
Behavioral Healthcare Executive

Advertisement

Advertisement

Browse Our Other Brands

Psych NP Institute

 

Psych Congress Network

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement